Figure 13From: Cellular and humoral immune responses against the Plasmodium vivax MSP-119 malaria vaccine candidate in individuals living in an endemic area in north-eastern Amazon region of BrazilFrequency of IgG subclasses. Prevalence of IgG1, IgG2, IgG3 and IgG4 antibodies against PvMSP-119 in IgG-positive malaria patients (n = 35). * p = 0.001, IgG3 versus IgG1; p < 0.0001, IgG3 versus IgG2 and IgG4.Back to article page